

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Restasis (cyclosporine ophthalmic emulsion)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Restasis (cyclosporine ophthalmic emulsion) 0.05%

APPROVAL CRITERIA

Requests for Restasis (cyclosporine ophthalmic emulsion) may be approved if the following criteria are met:

- I. Individual is 16 years of age or older; **AND**
- II. Individual is using to treat moderate to severe dry eye disease (AAO 2013); **AND**
- III. Individual has an abnormal result or response to one or more of the following dry eye disease diagnostic/assessment methods (AAO, 2013):
 - A. Tear break-up time (less than 10 seconds); **OR**
 - B. Ocular surface dye staining using fluorescein, rose bengal, or lissamine green dyes; **OR**
 - C. Schirmer test (aqueous tear production of less than or equal to 10 mm of strip wetting in 5 minutes); **OR**
 - D. Fluorescein clearance test/tear function index; **OR**
 - E. Tear osmolality (indicating tear film instability); **OR**
 - F. Tear lactoferrin concentrations in the lacrimal gland (decreased);
- AND**
- IV. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response to one artificial tear agent (AAO, 2013); **AND**
- V. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response to Xiidra (lifitegrast ophthalmic solution); **OR**
- VI. Individual has a known hypersensitivity to any ingredient in Xiidra which is not also present in Restasis.

Note: Increased tear production has not been seen in individuals concurrently using topical anti-inflammatory drugs or using punctual plugs.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Key References:

American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Dry Eye Syndrome. September 2013. Available from: <http://www.aao.org/preferred-practice-pattern/dry-eye-syndrome-ppp--2013>. Accessed on: January 27, 2017.

National Eye Institute (NEI). Facts About Dry Eye. Department of Health and Human Services and the National Institutes of Health website. Available from: <https://nei.nih.gov/health/dryeye/dryeye>. Last reviewed on: February 2013. Accessed on: January 27, 2017

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.